Cargando…

Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial

INTRODUCTION: A vaginal ring containing 25 mg of the antiretroviral dapivirine has demonstrated efficacy in reducing women’s risk of sexually acquiring HIV‐1; however, imperfect ring use likely diluted efficacy estimates in clinical trials. The amount of dapivirine remaining in returned rings may re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Elizabeth R, Hendrix, Craig W, van der Straten, Ariane, Kiweewa, Flavia M, Mgodi, Nyaradzo M, Palanee‐Philips, Thesla, Marzinke, Mark A, Bekker, Linda‐Gail, Soto‐Torres, Lydia, Hillier, Sharon L, Baeten, Jared M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673220/ https://www.ncbi.nlm.nih.gov/pubmed/33206462 http://dx.doi.org/10.1002/jia2.25634

Ejemplares similares

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention
por: Palanee-Phillips, Thesla, et al.
Publicado: (2015)

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women
por: Shapley-Quinn, Mary Kate, et al.
Publicado: (2022)

Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
por: Mayo, Ashley J., et al.
Publicado: (2021)

Increased Dapivirine Tissue Accumulation through Vaginal Film Codelivery of Dapivirine and Tenofovir
por: Akil, Ayman, et al.
Publicado: (2014)

Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States
por: Liu, Albert Y, et al.
Publicado: (2021)

Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial
por: Palanee-Phillips, Thesla, et al.
Publicado: (2018)

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study
por: Garcia, Morgan, et al.
Publicado: (2021)

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
por: Parikh, Urvi M., et al.
Publicado: (2021)

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
por: Nel, Annalene, et al.
Publicado: (2016)

Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis
por: Young, Alinda M., et al.
Publicado: (2023)

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls
por: Farr Zuend, Christina, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
por: Kusemererwa, Sylvia, et al.
Publicado: (2022)

Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High‐risk African Women
por: Kiweewa, Flavia Matovu, et al.
Publicado: (2019)

Dapivirine Bioadhesive Vaginal Tablets Based on Natural Polymers for the Prevention of Sexual Transmission of HIV
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel
por: Li, Jing, et al.
Publicado: (2019)

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
por: Ngure, Kenneth, et al.
Publicado: (2023)

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness
por: Glaubius, Robert, et al.
Publicado: (2019)

Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel
por: Dallal Bashi, Yahya H., et al.
Publicado: (2021)

Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention
por: Reidy, Meghan, et al.
Publicado: (2019)

Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance
por: Murphy, Diarmaid J., et al.
Publicado: (2021)

Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
por: Dezzutti, Charlene S., et al.
Publicado: (2016)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

Antitumor Activity and Mechanism of a Reverse Transcriptase Inhibitor, Dapivirine, in Glioblastoma
por: Liu, Weiwen, et al.
Publicado: (2018)

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions
por: Zheng, Ruohui, et al.
Publicado: (2022)

Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole
por: Valicherla, Guru Raghavendra, et al.
Publicado: (2021)

Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
por: Bhavaraju, Neeraja, et al.
Publicado: (2021)

Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine
por: Wang, Scarlet Xiaoyan, et al.
Publicado: (2016)

In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel
por: Murphy, Diarmaid J., et al.
Publicado: (2022)

Design of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis
por: Yang, Haitao, et al.
Publicado: (2019)

Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa
por: Leslie, Jonah, et al.
Publicado: (2021)

HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania
por: Tubert, Julia, et al.
Publicado: (2021)

An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women
por: Balkus, Jennifer E., et al.
Publicado: (2016)

End‐user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study
por: Montgomery, Elizabeth T, et al.
Publicado: (2019)

Editorial: Integration of HIV prevention with sexual and reproductive health services
por: Palanee-Phillips, Thesla
Publicado: (2023)

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
por: Donnell, Deborah, et al.
Publicado: (2023)

Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre‐exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial
por: Velloza, Jennifer, et al.
Publicado: (2021)

‘‘Ask the way from those who have walked it before”—Grandmothers’ roles in health-related decision making and HIV pre-exposure prophylaxis use among pregnant and breastfeeding women in sub-Saharan Africa
por: Reddy, Krishnaveni, et al.
Publicado: (2022)

Women’s Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa
por: van der Straten, Ariane, et al.
Publicado: (2014)

Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study
por: Beauchamp, Geetha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sm597bfsnc4k6l48vh4d4fnvpg